Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Targeted delivery of tropomyosin receptor kinase A agonists to the brain using magnetic resonance image-guided focused ultrasound
EF 2015-16
Résumé
Alzheimer's disease (AD) affects over half a million Canadians. AD is characterized by a gradual decline in cognition, which arises in response to several pathological changes in the brain including degeneration and dysfunction of nerve cells. At present, there is a critical need for AD therapies that enhance neuronal survival and function. Neurotrophins are proteins in the brain that induce neuronal survival and function, and can potentially halt cell loss observed in AD. In particular, nerve growth factor (NGF) has significant potential for the treatment of AD. The main challenges in clinical trials for NGF have been delivery to the brain in sufficient doses to impact cell function and controlling its delivery to specific brain areas to minimize off-target effects. Novel therapeutic agents with more favorable pharmacological properties than native NGF have been developed to address these limitations. These molecules are classified as tropomyosin receptor kinase A (TrkA) agonists which stimulate neuronal survival and activity by interacting with TrkA present on neurons. Moreover, a promising strategy for the delivery of therapeutics to specific brain areas is MRI-guided focused ultrasound (MRIgFUS) combined with microbubbles given intravenously. The interaction of ultrasound with circulating microbubbles allows for drugs injected intravenously to enter the brain at MRIgFUS-targeted areas. In this project, we will use animal models to establish the efficacy of TrkA agonists delivered to the brain using MRIgFUS. We expect that this treatment will improve neuronal health and cognition, while minimizing side effects. Overall, this research will provide key milestones in animal models prior to clinical translation for AD patients.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
350061
Name
Xhima Kristiana
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeted delivery of tropomyosin receptor kinase A agonists to the brain using magnetic resonance image-guided focused ultrasound
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alzheimer'S Disease; Cholinergic; Cognition; Focused Ultrasound; Nerve Growth Factor; Neurodegeneration; Neurogenesis; Neuronal Plasticity/Regeneration; Transgenic Mice; Tropomyosin Receptor Kinase A Agonist
Abstract
Alzheimer's disease (AD) affects over half a million Canadians. AD is characterized by a gradual decline in cognition, which arises in response to several pathological changes in the brain including degeneration and dysfunction of nerve cells. At present, there is a critical need for AD therapies that enhance neuronal survival and function. Neurotrophins are proteins in the brain that induce neuronal survival and function, and can potentially halt cell loss observed in AD. In particular, nerve growth factor (NGF) has significant potential for the treatment of AD. The main challenges in clinical trials for NGF have been delivery to the brain in sufficient doses to impact cell function and controlling its delivery to specific brain areas to minimize off-target effects. Novel therapeutic agents with more favorable pharmacological properties than native NGF have been developed to address these limitations. These molecules are classified as tropomyosin receptor kinase A (TrkA) agonists which stimulate neuronal survival and activity by interacting with TrkA present on neurons. Moreover, a promising strategy for the delivery of therapeutics to specific brain areas is MRI-guided focused ultrasound (MRIgFUS) combined with microbubbles given intravenously. The interaction of ultrasound with circulating microbubbles allows for drugs injected intravenously to enter the brain at MRIgFUS-targeted areas. In this project, we will use animal models to establish the efficacy of TrkA agonists delivered to the brain using MRIgFUS. We expect that this treatment will improve neuronal health and cognition, while minimizing side effects. Overall, this research will provide key milestones in animal models prior to clinical translation for AD patients.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Xhima, Kristiana
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~